Second primary cancers in the Vaud and Neuchâtel Cancer Registries.
An increasing proportion of new cancers is registered in patients who have received a previous cancer diagnosis. As data are inconsistent across studies, we provided information for populations long covered by valid cancer registration. Data were derived from the Swiss cancer Registries of Vaud and Neuchâtel (885,000 inhabitants). Patients diagnosed with a new malignancy (except skin basal and squamous cell carcinomas) during the period 2005-2010 were included. Over the period 2005-2010, 24,859 patients were registered with incident cancer. Of these, 3127 (13%) had multiple primary cancers and 578 (2.3%) were synchronous. Breast, prostate, colorectum, skin, melanomas, and squamous cell carcinomas of the head and neck (SHN) and bladder/ureter were the most common sites of first neoplasms, whereas breast, lung, colorectum, prostate, melanoma, and SHN were the most common sites of second neoplasms. The most common pairing was breast with breast (31% synchronous), followed by the bladder/ureter with the prostate (72% synchronous), prostate with the colorectum, SHN with SHN, and SHN with lung. Five-year crude survival of patients with synchronous cancers (34%) was not significantly lower than that of patients with single neoplasms (39%). This population-based study indicates that about one in eight incident neoplasms in these mature registries are second neoplasms and almost 1/40 patients are diagnosed with synchronous primary cancers. These are related to shared genetic and environmental factors as well as diagnostic and therapeutic procedures. As cancer diagnosis and survival is likely to improve, the proportion of patients with multiple primary cancers will further increase in the future.
aVaud Cancer Registry and Cancer Epidemiology Unit, Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Lausanne bNeuchâtel Cancer Registry, Department of Health and Social Affairs, Neuchâtel, Switzerland cDepartment of Epidemiology, IRCCS - Istituto di Ricerche Farmacologiche 'Mario Negri' dDepartment of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy.
Fabio
F
Levi
Lalao
L
Randimbison
Blanc-Moya
BM
Rafael
Maspoli-Conconi
MC
Manuela
Carlo
C
La Vecchia
D000368:Aged; D001943:Breast Neoplasms / Q000453:epidemiology / Q000401:mortality; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology / Q000401:mortality; D002295:Carcinoma, Transitional Cell / Q000453:epidemiology / Q000401:mortality; D015179:Colorectal Neoplasms / Q000453:epidemiology / Q000401:mortality; D005260:Female; D006258:Head and Neck Neoplasms / Q000453:epidemiology / Q000401:mortality; D006801:Humans; D008175:Lung Neoplasms / Q000453:epidemiology / Q000401:mortality; D008297:Male; D008545:Melanoma / Q000453:epidemiology / Q000401:mortality; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000453:epidemiology* / Q000401:mortality; D016609:Neoplasms, Second Primary / Q000453:epidemiology* / Q000401:mortality; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000401:mortality; D012042:Registries; D012878:Skin Neoplasms / Q000453:epidemiology / Q000401:mortality; D000077195:Squamous Cell Carcinoma of Head and Neck; D013557:Switzerland / Q000453:epidemiology; D014516:Ureteral Neoplasms / Q000453:epidemiology / Q000401:mortality; D001749:Urinary Bladder Neoplasms / Q000453:epidemiology / Q000401:mortality